Text NMHEART to 43506 to download our referral app.
Follow us on Twitter @NMCardioVasc.
Find out more at breakthroughsforphysicians.nm.org.

Northwestern Medicine Featured Cardiovascular Clinical Research 

The mission of Bluhm Cardiovascular Institute’s Clinical Trials Unit of Northwestern University is to enhance, foster and support high-quality, innovative clinical research that advances medical discoveries for the prevention, detection and treatment of cardiovascular disease.

By pursuing advancement through collaboration with reputable healthcare community members, including device and pharmaceutical companies, the Clinical Trials Unit facilitates each investigator’s ability to drive science forward. We strive to participate in diversified clinical research across the cardiovascular spectrum that produces breakthrough treatments and improved patient outcomes.

The Clinical Trials Unit is partnered in its research endeavors with Northwestern Memorial HealthCare, including affiliates at:

  • Northwestern Memorial Hospital
  • Northwestern Medical Group
  • Northwestern Memorial Foundation
  • Northwestern Medicine Lake Forest Hospital
  • Northwestern Medicine Central DuPage Hospital
  • Northwestern Medicine Delnor Hospital
  • Northwestern Medicine Kishwaukee Hospital

These affiliations strengthen our ability to conduct meaningful clinical research and provide common infrastructure necessary to bring medical innovations to Northwestern Medicine patients as quickly as possible. Our varied portfolio includes more than 100 ongoing clinical trials, with 60 actively enrolling clinical trials, involving more than 10,000 patient participants. Our robust clinical research program allows us to offer patients access to treatments and therapies that are available at only a few medical centers nationwide.

To view all Northwestern Medicine cardiovascular clinical trials, visit Bluhm Cardiovascular Institute's Clinical Trials Unit of Northwestern University.

312.NM.HEART (664.3278) | heart.nm.org | Inquiries: BCVI_info@nm.org

 ©2021 by Northwestern Medicine® and Northwestern Memorial HealthCare. Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University.

 Northwestern Medicine ® | 251 East Huron Street | Chicago, Illinois 60611 | nm.org

Northwestern Memorial Hospital has the highest-ranked Cardiology and Heart Surgery program in Illinois, ranked top 10 in the nation by U.S. News & World Report, 2020-21. The 2,000-person strong cardiovascular team at Northwestern Medicine is proud of this honor and our many notable clinical achievements.

To refer a patient for clinical care, a second opinion or consideration in a clinical trial, please contact us at 312.NM.HEART (312.664.3278) or download the NM Cardiovascular MD Referral app from the App Store or Google Play.

Sanjiv J. Shah, MD
Medical Director, Bluhm Cardiovascular Institute’s Clinical Trials Unit of Northwestern University
sanjiv.shah@northwestern.edu
Twitter: @HFpEF

Sanjiv J. Shah, MD
Download the App

If you have any questions or need assistance with NM Cardiovascular MD Referral, please call 844.926.7300 or email bcvi.support@flarehealth.app

You many also search for “NM Cardiovascular MD Referral” on the Apple App Store or Google Play Store, or text NMHEART to 43506 for a link to download the app.

NM Cardiovascular MD Referral is a secure and reliable mobile app that makes it easy for you to refer to, and collaborate with, Northwestern Medicine cardiovascular physicians. This HIPAA-compliant app gives you information about each physician’s area of expertise, accepted insurance, office locations and phone numbers.

This app also allows you to view a comprehensive listing of current Northwestern Medicine cardiovascular clinical trials, and to search for clinical trials by name or condition.

Advancing Medical Discoveries at Northwestern Medicine Through
Diversified Clinical Research Across the CV Spectrum

Access to World-Class Cardiovascular Physicians and Clinical Trials

Contact Us

Facebook logo
Twitter logo
YouTube logo
Northwestern Medicine campus

National Principal Investigator:
Sanjiv J. Shah, MD
Principal Investigator:
Ravi B. Patel, MD, MSc

Rebalance-HF

This clinical trial is being conducted to assess safety and effectiveness of catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) in patients having heart failure with preserved ejection fraction (HFpEF). Study participants will be randomized 1:1 to either ablation of the GSN using the Axon Ablation System or a sham procedure. Primary study endpoints include device- or procedure-related serious adverse events and a reduction in exercise capillary wedge pressure at one month.

TRISCEND II Pivotal

Principal Investigator:
Charles J. Davidson, MD

This clinical trial is enrolling patients to evaluate the safety and effectiveness of the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement system with Optimal Medical Therapy (OMT) compared to OMT alone in the treatment of patients with at least severe tricuspid regurgitation. The primary endpoints include composite MAEs at 30 days, TR grade reduction to moderate, mild or trace/none at six months; and pre-specified outcomes at 12 months. 

National Co-Principal Investigator:
Patrick M. McCarthy, MD
Principal Investigator:
Charles J. Davidson, MD

REPAIR MR

This clinical trial is enrolling patients with severe primary MR who are at moderate surgical risk and have been determined to be suitable candidates for mitral valve surgery. Eligible participants will be randomized 1:1 to receive the MitraClip device or traditional mitral valve repair surgery. The primary endpoint includes all-cause mortality, stroke, cardiac hospitalization, or acute kidney injury requiring renal replacement therapy at two years.

CARDIO-TTRansform

Steering Committee Member and Principal Investigator:
Sanjiv J. Shah, MD

This phase 3 global, double-blind, randomized, placebo‑controlled study is enrolling patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) to determine if AKCEA-TTR-LRx, an investigational antisense oligonucleotide drug (i.e., TTR silencer), is safe and effective at slowing the progression of cardiomyopathy and improving quality of life for people living with ATTR-CM. The primary endpoint is a composite of CV-mortality and recurrent CV clinical events including cardiac hospitalizations at Week 120.

CARDIO-TTRansform

Principal Investigator:
Bradley P. Knight, MD

The purpose of this non-randomized, multi-center trial is to provide data demonstrating the safety and effectiveness of the PulseSelect™ PFA System for the treatment of atrial fibrillation (AF). The clinical trial will provide first in human insights into the safety and device function of the PulseSelect PFA System for pulmonary vein isolation (PVI) as a treatment for AF. The primary safety endpoints include device- or procedure-related serious adverse events at 30 days and presence of pulmonary vein stenosis, phrenic nerve injury or atrioesophageal fistula at six months.

CARDIO-TTRansform

Principal Investigator:
Andrew W. Hoel, MD

This clinical trial is being conducted to assess safety and effectiveness of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE) device in patients who have an aortic aneurysm involving the visceral branch blood vessels requiring treatment. TAMBE is designed to be the first complete off-the-shelf solution for the treatment of this complex disease. The co-primary endpoints include uncomplicated technical success/procedural safety through Day 30 and clinically significant intervention/lesion-related mortality at 12 months.